Science Corp., led by former Neuralink president Max Hodda, is advancing brain‑computer interface technology through two main avenues. The company has refined the Prima retinal implant, originally acquired from Pixium Vision, and is completing clinical trials that show most patients regain functional reading ability. At the same time, Science Corp. is developing bio‑hybrid neural interfaces that grow engineered neurons on a wafer‑like device to augment brain function. Both efforts aim to create commercially viable medical products while laying groundwork for longer‑term goals such as optogenetic gene therapy and large‑scale neural augmentation. Leia mais →